title: Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma.
abstract: Up to 50% of patients with Hodgkin lymphoma and diffuse large B-cell lymphoma will relapse, requiring additional therapy. Although surveillance imaging is commonly performed in clinical practice, its ability to identify asymptomatic relapses and improve survival for patients is not well defined. We evaluated the surveillance imaging role in relapse detection and reviewed its impact on survival for relapsed patients, and found that current imaging approaches do not detect most relapses prior to clinical signs and symptoms or improve survival.
authors.affiliation: Winship Cancer Institute, Emory University, Atlanta, GA; and.
authors.forename: Jonathon B
authors.initials: JB
authors.lastname: Cohen
authors.affiliation: Winship Cancer Institute, Emory University, Atlanta, GA; and.
authors.forename: Madhusmita
authors.initials: M
authors.lastname: Behera
authors.affiliation: Mayo Clinic, Rochester, MN.
authors.forename: Carrie A
authors.initials: CA
authors.lastname: Thompson
authors.affiliation: Winship Cancer Institute, Emory University, Atlanta, GA; and.
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Flowers
mesh_terms: D006689:Hodgkin Disease / Q000000981:diagnostic imaging*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging*; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography; D014057:Tomography, X-Ray Computed